Abstract
Background: Hepatocellular carcinoma (HCC)is endemic in parts of Asia and Africa and most patients are not suitable for treatment with a curative approach. Little is known about the cost of palliative care for HCC.
Objective: To determine: (i) patient-specific costs of palliative care of HCC; and (ii) individual factors that drive patient-specific costs and to develop a model of cost per case under alternative circumstances.
Methods: 204 patients with inoperable HCC were prospectively tracked from first hospitalisation until death for health service utilisation. A societal perspective of cost was taken, including costs of formal and informal services incurred by payers, caregivers and patients. Observational data from a large Hong Kong cancer care programme were used. A regression analysis was performed using formal costs only, with the cost per observed day as the dependent variable.
Results: The median survival was 95 days and the mean observation period was 153 days. The mean value per person for formal healthcare cost was 30 983 Hong Kong dollars [$HK] ($US3872, 1998 values). The distribution of cost valueswere positively skewed. The regression analysis showed that age, days of observation and survival were negatively related to cost per observed day, and the Child-Pugh grading of severity of liver cirrhosis was positively related to cost per observed day. A sensitivity analysis based on the regression equation indicated that nonsurvivorship doubles the cost per case, increased severity as measured by the Child-Pugh Index adds about 50% to the cost, and chemotherapy increases cost 2-fold.
Conclusions: The relatively modest average cost per patient with HCC in Hong Kong reflects the short median survival and subsequently the limited use of inpatient care and chemotherapy.
Similar content being viewed by others
References
Simonetti RG, Camma C, Fiorella F, et al. Hepatocellular carcinoma. Dig Dis Sci 1991; 36: 962–72
Hong Kong Cancer Registry. Cancer incidence and mortality in Hong Kong 1993–1994. Hong Kong: Hospital Authority, 1998
Okuda K. Primary liver cancers in Japan. Cancer 1980; 45: 2663–72
Shiu W, Dewar G, Leung N, et al. Hepatocellular carcinoma in Hong Kong: clinical study on 340 cases. Oncology 1990; 47: 241–5
Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866–74
Bennett WG, Inoue Y, Beck R, et al. Estimates of cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65
Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interpheron in the treatment of chronic active hepatitis C. Med J Aust 1994; 160: 268–72
Sarasin FPGE, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422–34
Wong LL, McFall P, Wong LMF. The cost of dying of end-stage liver disease. Arch Intern Med 1997; 157: 1429–32
Durand-Zaleski I, Earlam S, Fordy C, et al. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver cancer. Cancer 1998; 83: 882–8
Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesoghageal varices. Br J Surg 1973; 60: 646–9
Welsh Office, E.A.S.S.D. Welcan UK. Cardiff. Economics and Statistical Services Division, Welsh Office, 1998
Alberta Health. 1995/6 technical portion of the diagnostic imaging common procedure/examination lost (cpel). Edmonton, Alberta, Canada: Alberta Health, 1995
Groupe d’Etude et de. Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256–61
Lau WY, Ho S, Leung WT, et al. Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intraarterial infusion of yttrium-90 microsphere. Int J Radiat Oncol 1998; 40: 583–92
Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 1988; 62: 479–83
Felder S, Meier M, Schmitt H. Health care expenditures in the last month of life. J Health Econ 2000; 19: 679–95
Acknowledgements
This project is supported by a Full Project Grant of the Health Services Research Committee, Hospital Authority, Hong Kong. The authors would like to acknowledge the support of the Hospital Chief Executives and Finance Managers of Prince of Wales Hospital, Shatin Hospital and Bradbury Hospice during the course of this project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chan, A.T.C., Jacobs, P., Yeo, W. et al. The Cost of Palliative Care for Hepatocellular Carcinoma in Hong Kong. Pharmacoeconomics 19, 947–953 (2001). https://doi.org/10.2165/00019053-200119090-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200119090-00006